Objective
Drug hypersensitivity to antibiotics, mainly Beta-lactams (BLCs) affects more than 2.5 million European citizens. Moreover, preventable adverse drug reactions are estimated in additional hospitalization costs of 1750-4500 €/patient. Currently, the allergy diagnosis is mainly based on the information given by invasive, single, and risky in vivo assays. In daily practice, few in vitro diagnostic methods are available and only used at the tertiary health services. These tests also lack of sensitivity (>0.35 kUA/L) and selectivity (<98%), resulting in an inaccurate diagnosis, analyze few drugs allergens (5), are time consuming (60-180 min), and expensive (30 €/allergen).
COBIOPHAD aims the development of an innovative in vitro diagnostic (IVD) device for diagnosis of IgE-mediated drug allergies by building an integrated biophotonic system based on compact disc technology. For that, key enabling technologies will be integrated in order to achieve high sensitive (<0.1 kUA/L), selective (>98%), multiplexed (10 BLCs), rapid (30 min), and low-cost (2.4 €/allergen) drug allergy test. The solution involves an advanced approach to the diagnosis and management of drug allergy with the aim to ameliorate patient safety.
The consortium comprises multidisciplinary knowledge on optics, electronics, advanced materials, biotechnology, smart microstructures, microfluidics, surface/organic chemistry, allergy, manufacturing systems, and telecom networking. Also, the key industrial actors, present in the consortium, will contribute to the manufacturing and placing the product on the IVD market.
Fields of science
Programme(s)
Topic(s)
Funding Scheme
IA - Innovation actionCoordinator
46022 Valencia
Spain
See on map
Participants (12)
E14 9NN London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
34000 Montpellier
See on map
NW6 1JZ London
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
41468 Neuss
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
46026 Valencia
See on map
077125 Magurele
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
7034 Trondheim
Participation ended
5081 Anif
Participation ended
46022 Valencia
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
5081 Anif
See on map
46023 Valencia
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
7034 Trondheim
See on map